๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 18 Guangzhou 18 Beijing 15 Changsha 10 Hangzhou 8
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai18 Guangzhou18 Beijing15 Changsha10 Hangzhou8
All 39 locations
Target enrolment
to

Trials with a site in Shanghai

18 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
NCT07697586NSCLC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
206
Jilin City, Shanghai
2026-08-07
Recruiting
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors
NCT07274813Advanced/Metastatic Solid Tumors, NSCLC
Shanghai Henlius Biotech
Phase EARLY_PHASE1
254
Shanghai, Xi'an
2025-12-29
Recruiting
HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
NCT07169552NSCLC
DrugHC010
HC Biopharma Inc.
Phase 2
50
Shanghai
2025-12-09
Not yet open
Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
NCT07156604NSCLC, Neoadjuvant Therapy
Fudan University
Phase 2
30
Shanghai
2025-09-30
Not yet open
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
NCT07086326NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xiโ€™an, Hangzhou
2025-07-31
Active, closed
JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations
NCT06940401NSCLC
DrugJS111
Suzhou Junjing BioSciences Co., Ltd.
Phase 1/2
44
Shanghai
2025-04-30
Recruiting
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
NCT05798845NSCLC
Shanghai Chest Hospital
Phase 2
124
Shanghai
2025-02-20
Recruiting
Clinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field Ablation Devices in the Treatment of Lung Tumors
NCT06739031NSCLC
Energenx Medical LTD.
Not applicable
126
Shanghai
2024-12-25
By invitation
Perioperative Treatment Outcomes of Early NSCLC
NCT06610240NSCLC
Shanghai Chest Hospital
Observational
500
Shanghai
2024-11-01
Active, closed
Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC
NCT06448910NSCLC, Locally Advanced Lung Carcinoma
Fudan University
Phase 2
41
Shanghai
2024-07-01
Recruiting
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
NCT05994131NSCLC
InxMed (Shanghai) Co., Ltd.
Phase 1/2
110
Shanghai
2023-07-13
Recruiting
A Study of XZB-0004 in Patients With Solid Tumors
NCT05772455Advanced Solid Tumor, NSCLC
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
128
Shanghai
2023-03-24
Recruiting
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
NCT05382728NSCLC, EGFR Activating Mutation
TYK Medicines, Inc
Phase 3
680
Changsha, Shanghai
2022-06-08
Active, closed
Crizotinib Continuation Clinical Study
NCT05160922NSCLC, ALCL, IMT
Pfizer
Phase 4
27
Beijing, Fuzhou, Guangzhou, Changchun, Wuhou District, Hangzhou, Shanghai
2021-12-27
Active, closed
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
NCT05078931NSCLC
Shanghai Chest Hospital
Phase 2
35
Shanghai
2021-10-27
Recruiting
Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations
NCT05701787NSCLC, NSCLC Stage IV, NSCLC, Recurrent
Shanghai Chest Hospital
Observational
500
Shanghai
2019-01-01
Recruiting
Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer
NCT04522687NSCLC, Esophageal Squamous Cell Carcinoma, Thymic Epithelial Tumor
Shanghai Cancer Hospital, China
Observational
500
Shanghai
2012-01-01
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

11 of the 18 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 4 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 18 studies
PhaseStudiesRecruitingShare
Phase 28444.4%
Observational3216.7%
Phase 1/22111.1%
Not applicable115.6%
Phase 1115.6%
Phase 3115.6%
Phase 4105.6%
Phase EARLY_PHASE1115.6%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Shanghai Chest Hospital42
Fudan University31
Energenx Medical LTD.11
HC Biopharma Inc.11
InxMed (Shanghai) Co., Ltd.11
Pfizer10
Shanghai Cancer Hospital, China11
Shanghai Henlius Biotech11
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.11
Suzhou Junjing BioSciences Co., Ltd.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.